Evaluation of Femur Fracture Risk in Soft-Tissue Sarcoma of the Thigh Treated with Intensity- Modulated Radiation Therapy (IMRT) Michael R. Folkert, MD.

Slides:

Advertisements

Similar presentations

Danny Indelicato, MD CTOS 2012 Ewing Sarcoma of the Axial Skeleton: Early Outcomes from the University of Florida Proton Therapy Program.

Advertisements

IMRT, Designed with Evidence-Based Bone Avoidance Objectives, Reduces the risk of Bone Fracture in the management of Extremity Soft Tissue Sarcoma Colleen.

CTOS, Boca Raton, 2005 A Radiation Treatment Planning Comparison for Lower Extremity Soft Tissue Sarcoma: Can the Future Surgical Wound Be Spared? Anthony.

In-Depth Analysis of Wound Complications Following Preoperative Radiotherapy for Lower Extremity Soft Tissue Sarcoma Patients Colleen Dickie MSc, MRT(T)(MR)

Overskrift her Navn på oplægsholder Navn på KU- enhed For at ændre ”Enhedens navn” og ”Sted og dato”: Klik i menulinjen, vælg ”Indsæt” > ”Sidehoved / Sidefod”.

Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the.

H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.

Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.

IMRT vs. BRACHYTHERAPY FOR SOFT TISSUE SARCOMA. EXTERNAL RT IN STS NCI Trial (Yang JC et al, JCO 1998) Extremity / Superficial Trunk STS (n=141) LSS Alone.

Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.

The Health Roundtable 1-1b_HRT1215-Session_HEGI_JOHNSON_WESTMEAD_NSW Volumetric Modulated Arc Therapy for Stereotactic Body Radiotherapy in Early Lung.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.

Thomas F. DeLaney MD, Aashish D. Bhatt MD, Alex Jacobson BS, Richard Y. Lee MD, PhD, Christine Giraud BS, Joseph H. Schwab MD, MS, Francis J. Hornicek.

PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;

Pulmonary Metastasis From Osteosarcoma Multi-factorial analysis of survival at first lung involvement Ali Aljubran, Martin Blackstein for the University.

Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.

Description of fracture with endocrine therapy use in older breast cancer survivors in a population-based setting Taryn Becker 123, Geoff Anderson 123,

Comparison of MRI Perfusion and PET-CT in Differentiating Brain Tumor Progression from Radiation Injury after Cranial Irradiation T. Jonathan Yang, M.D.

CTOS 2013 Radiation Oncology Session Discussion Elizabeth H Baldini, MD, MPH Associate Professor of Radiation Oncology Harvard Medical School Brigham and.

Evaluating a Nomogram for the Development of Radiation Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer Treated with 3D and Intensity Modulated.

INTRODUCTION  The majority of clinical trials addressing outcomes in limited- stage small cell lung cancer (LS-SCLC) following definitive chemoradiotherapy.

Will my Glaucoma patient lose vision ?

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;

Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,

Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.

Phase II Trial of Continuous Course Re- irradiation Concurrent with Weekly Cisplatinum and Cetuximab for Recurrent Squamous Cell Carcinoma of The Head.

CTOS Soft Tissue Sarcoma of the Extremity Comparison of Conformal Post-operative Radiotherapy (CRT) and Intensity Modulated Radiotherapy (IMRT)

Quantitative Dosimetric Analysis Of Patterns Of Local Relapse After IMRT For Primary Extremity Soft Tissue Sarcomas Ryan M. Lanning, Sean L. Berry, Michael.

An Assessment of Factors Affecting Outcome in Patients Presenting with Metastatic Soft Tissue Sarcoma Peter Ferguson MD1,2, Benjamin Deheshi MD1,2, Anthony.

Validity of more than 30Gy radiation therapy for long-surviving patients with painful bone metastases E.Katayama 1,2, H.Okada 1, I.Asakawa 2, T.Tamamoto.

Ye, Sung-Joon, Ph.D. Ove, Roger, M.D., Ph.D.; Shen, Sui, Ph.D.

Predicting toxicity for patients with advanced Gastrointestinal Stromal Tumors (GIST) treated with imatinib mesylate : an EORTC/ISG/AGITG randomized trial.

CORRELATION OF MSTS 87 & TESS FUNCTIONAL EVALUATION SCORES FOLLOWING ENDOPROSTHETIC REPLACEMENT FOR BONE SARCOMAS A Mahendra 1, AM Griffin 1, C Yu 1, Y.

Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,

Ki Hyuk Sung, MD Department of Orthopaedic Surgery Seoul National University Bundang Hospital Rate of correction after asymmetrical physeal suppression.

Permanent Interstitial Implants Ideal strategy to curatively manage small volume gynecologic malignancies Can deliver high cumulative radiation dose to.

Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.

EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.

Risk assessment for VTE Dr Roopen Arya King’s College Hospital.

Acknowledgements This report differs from the submitted abstract due to further subdivision of patients into analytic and non- analytic, and focus on the.

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

CTOS, Berlin 2014 The influence of time interval between preoperative radiation and surgical resection on the development of wound healing complications.

FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,

CTOS years Experience of Management of Malignant Phyllodes Tumor and Breast Sarcoma at Princess Margaret Hospital Princess Margaret Hospital &

LOCAL CONTROL MODALITY AND OUTCOME IN EWING SARCOMA OF THE FEMUR: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP Najat C. Daw, Nadia N. Laack, Elizabeth J.

14 th Annual Meeting of the Connective Tissue Oncology Society November 13-15, 2008, London, UK Oliver Zivanovic, Mario M. Leitao, Alexia Iasonos, Lindsay.

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

The Influence of Age on Morbidity in Primary High Grade Sarcoma of the Extremity K. Alektiar, M. Brennan, S. Singer Memorial Sloan-Kettering Cancer Center.

Tumor Location Correlates with Radiation Pneumonitis after Stereotactic Body Radiation Therapy (SBRT) for Primary and Oligometastatic Lesions of the Lung.

Local Recurrence Growth Rate Predicts Outcome In Locally Recurrent Retroperitoneal Liposarcoma James Park, MD, Li-Xuan Qin, PhD, Francesco Prete, MD Murray.

Increased Local Control of Lung and Liver Tumors Associated with Dose-Escalated Stereotactic Body Radiation Therapy (SBRT) Supports a Dose-Response Relationship.

Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.

Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.

Saad El Din I, M.D *, Abd El AAl H, M.D *, Makaar W, M.D *, El Beih D, M.Sc †, Hashem W, M.Sc * *Department of Clinical Oncology and Radiotherapy, Kasr.

SC-PM6: Prediction Models in Medicine: Development, Evaluation and Implementation Michael W. Kattan, Ph.D. Ewout Steyerberg, Ph.D. Brian Wells, M.S., M.D.

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.

DEPT OF RADIATION ONCOLOGY Prognostic Value of Post-Radiotherapy FDG PET in Head and Neck Cancer after Intensity Modulated Radiation Treatment Heming Lu.

Results of Definitive Radiotherapy in Anal Canal Carcinoma

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.

Volumetric Modulated Arc Therapy (VMAT) versus Intensity Modulated Radiation Therapy (IMRT) for Anal Carcinoma Heather Ortega, BSRT(T), CMD, Kerry Hibbitts,

Insert tables Insert graphs Insert figure

Authors: Nahhas, Mohammed, and Isler, Marc

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,

高雄榮民總醫院耳鼻喉頭頸部林陞樵林曜祥康柏皇張庭碩

Rarer Bone Tumors Thomas F. DeLaney, M.D. Co-Director: Sarcoma Program

Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &

Presentation transcript:

Evaluation of Femur Fracture Risk in Soft-Tissue Sarcoma of the Thigh Treated with Intensity- Modulated Radiation Therapy (IMRT) Michael R. Folkert, MD PhD, Samuel Singer, MD, Murray F. Brennan, MD, Patrick J. Boland MD, Kaled M. Alektiar, MD Departments of Radiation Oncology, Surgery, and Orthopedic Surgery Memorial Sloan-Kettering Cancer Center New York NY USA

Disclosures None of the authors have anything to disclose.

Introduction Researchers at PMH 1 have previously examined the risk of femur fracture in patients treated with adjuvant conventional RT for thigh sarcoma. 101 patients were identified with 22 RT- associated fractures; risk factors were assessed and incorporated into a nomogram. 1.Gortzak et al, Cancer 2010; 116(6):

Objective: Preliminary data has suggested a lower risk of fracture when using IMRT. We compared the observed risk of femoral fracture in primary soft-tissue sarcoma (STS) of the thigh treated with adjuvant IMRT at MSKCC to the expected risk using the Princess Margaret Hospital (PMH) nomogram.

Methods Patients treated with limb-sparing surgery and adjuvant IMRT between 2/2002 and 11/2009 for primary STS of the thigh were included (84); those receiving prophylactic internal fixation were excluded (2). –Median followup was 44 months (range months) –Mean of 52 months. Expected femoral fracture risk was calculated using the PMH nomogram. –Direct calculation using maximum likelihood estimates, with P(fracture) = 1/(1+e -Σ(MLE) ) Cumulative risk of fracture was estimated using Kaplan-Meier statistics; univariate and multivariate analysis was performed.

N (%)PMH N (%) GenderFemale35 (43%)52 (51.5%) Male47 (57%)49 (48.5%) Age range(19-88)(20-89) CompartmentAnterior38 (46%)44 (43.6%) Posterior26 (32%)13 (12.9%) Medial/Adductor18 (22%)20 (19.8%) "Other"024 (23.8%) Tumor size range (cm)(2.5-31)(1-28) Extent of Periosteal Stripping<10cm66 (80.5%)80 (79.2%) 10-20cm9 (11%)16 (15.8%) >20cm7 (8.5%)5 (5%) Radiation Dose (Gy) Dose ≥ 60 Gy69 (84.1%)65 (64.4%) Dose < 60 Gy13 (15.9%)36 (35.6%) ChemotherapyYes31 (38%)0 (0%) No51 (62%)101 (100%) Patients

Results At a median followup of 44 months: –There were 5 (6.1%) fractures. –The median time to fracture was 12.2 months (range months). –The cumulative risk of fracture using IMRT at 5 years was 8.6% (95% CI %).

Results – Comparison to PMH Crude Rates Median time to fracture in PMH cohort was 4 years. The 5 year crude risk in PMH cohort (15/22 fractures in 101 patients) was 14.8%, compared to 6.1% in the current study using IMRT. 1.Gortzak et al, Cancer 2010; 116(6):

Observed vs. Expected Fracture Risk The PMH femur fracture nomogram was predictive in the IMRT cohort. The observed crude risk of fractures was 6.1% compared to 26.4% expected crude risk from the PMH nomogram.

Predictors of fracture: univariate analysis (5 years) P value Gender.403 Age (continuous).315 Compartment of Thigh.191 Tumor Size (continuous).012 Periosteal stripping.049 Dose > 60 Gy.519 Chemotherapy On MVA, these factors did not retain significance.

Conclusions In this study, the crude observed risk of femoral fracture in patients treated with IMRT (6.1%) is less than the expected risk using the PMH nomogram (26.4%). Longer followup duration in the PMH cohort may contribute to this difference, but even reporting cumulative 5-year risk in the IMRT cohort, the rate was only 8.6%; longer followup in our cohort is still needed. Established predictors of femoral fracture such as gender, age, tumor size, and periosteal stripping seem to exert less influence when using IMRT.

Thank you for your kind attention. Any questions?

PMH Nomogram The PMH nomogram for prediction of femur fracture risk was based on variables found to be associated on multivariate logistic regression analysis. 1 The fit of their model on the basis of the receiver-operating characteristic (ROC) curve was excellent, with an area under the curve (AUC) of Gortzak et al, Cancer 2010; 116(6):

Dosimetric Concerns When expanding GTV to CTV, nearby bone is excluded. A longitudinal strip of skin is spared to protect lymphatic drainage. Total Dose or Volume ≤To: 64%V 40 Gy 37 GyMean Dose 66 GyMax Point Dose

Prophylactic IM Nail Prophylactic femoral intramedullary (IM) nailing has been raised as a consideration for patients at high risk of fracture. While this may potentially benefit high-risk patients treated with conventional radiation therapy, there is no clear indication at this time for patients treated with IMRT.

Dose to Fracture Site Performing dosimetric analysis on site of fracture relative to initial treatment (ongoing).

Results, Univariate Analysis Predictors of fracture on univariate analysis (at 5 years); on MVA, these factors did not retain significance. 5 Year Cumulative RiskP value Female13.7% (0-30.5%).392 Male4.8% (0-11.6%) Age ≤ 50 0%.100 Age > % (0-25.6%) Compartment, Anterior19.9% ( %).037 Compartment, Posterior0.0% Compartment, Medial0.0% Tumor Size, ≤ 10cm0.0%.038 Tumor Size, > 10 cm 16.9% ( %) <10 cm periosteal stripping7.5% (0-16.5%) cm periosteal stripping0.0% > 20 cm periosteal stripping31.4% (0-68.6%) Dose ≤ 60 Gy 0.0%.305 Dose > 60 Gy10.2% (0-19.6%) No Chemotherapy9.1% (0-19.9%).817 Chemotherapy6.6% (0-15.6%)